Purpose: The effectiveness of anastrozole for breast cancer prevention
Anastrozole, which has been used for many years as a breast cancer
In data A daily pill that halves the risk of breast cancer is to be rolled out on the NHS in “a new era for cancer prevention”
Anastrozole is authorised for treating breast cancer in postmenopausal women and has been used off label in some cases for prevention, but
47 There are no data from randomized trials for tamoxifen, exemestane, or anastrozole to be given for longer than 5 years for For women with early breast cancer, treatment with an aromatase inhibitor (alone or after tamoxifen) lowers the risk of [1]: Breast cancer recurrence (a return of breast cancer) Breast cancer in the opposite breast
It works by reducing the amount of estrogen the body can make by blocking an enzyme called aromatase
The new license for prevention will hopefully raise awareness and remove one of the barriers for the uptake of this treatment
Please use one of the following formats to cite this article in your essay, paper or report: APA
The large 61% reduction in breast cancer incidence in the first 5 years has been maintained in subsequent follow-up to 12 years
34; 95% CI, 1
Anastrozole (Arimidex®) for early breast cancer in hormone receptor-positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen (November 2006) Recommended with restrictions
The most commonly used medicines to lower breast cancer risk are tamoxifen and raloxifene
It’s been found to be more effective than the former leading drug for breast cancer treatment, tamoxifen
Less estrogen in your body makes it less likely that your prior cancer will return and less likely that a new breast cancer tumor will develop